Speaker: Guillermo Umpierrez, MD

Module 1: The importance of comprehensive control in T2D, weight as a fundamental factor in evaluation and treatment goals, and complications of T2D outside control targets

After watching the presentation, attendees should be able to:

• Describe the glycemic control targets according to international guidelines, outline the complications related to poor weight and glucose control in patients with T2D.

Speaker:  Juan Pablo Frias, MD

Module 2: Tirzepatide: A New Therapeutic class for the treatment of T2D

After watching the presentation, attendees should be able to:

• Explain the mechanism of action of tirzepatide as a new therapeutic class for T2D.
• Define the characteristics of patients who can benefit from tirzepatide.

Speaker: Juan Pablo Frias, MD

Module 3: Tirzepatide and its Potency in glycemic control

After watching the presentation, attendees should be able to:

• Describe the glucose reduction results from the SURPASS Clinical Trial.

Speaker: Rodolfo Galindo, MD FACE

Module 4: Tirzepatide and the effect in weight control in T2D

After watching the presentation, attendees should be able to:

• Present the weight reduction results from the SURPASS clinical trial program.
• Highlight the benefits of weight loss in preventing complications in patients with T2D.

Speaker: Rodolfo Galindo, MD, FACE

Module 5: Tirzepatide dose titration and adverse events

After watching the presentation, attendees should be able to:

• Present the adverse effects associated with Tirzepatide treatment in patients with T2D.
• Understand the importance of titration to improve gastrointestinal tolerability.

Speaker: Guillermo Umpierrez, MD

Module 6: Weekly Incretin (GLP1vs GIP/GLP1) vs SGLTs and when to use them

After watching the presentation, attendees should be able to:

• Compare the mechanisms of action, efficacy, and safety profiles of weekly incretin-based therapies versus SGLT2 inhibitors.
• Evaluate the Cardiometabolic-renal benefits of each treatment class.